Results 91 to 100 of about 48,541 (237)

Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay

open access: yesMovement Disorders, EarlyView.
Abstract Background The cerebrospinal fluid alpha‐synuclein seed amplification assay (CSFasynSAA) detects alpha‐synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined.
Sarah M. Brooker   +30 more
wiley   +1 more source

Author Correction: Synthesis and comparative evaluation of 177Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probes

open access: yesScientific Reports, 2022
Amit Kumar Sharma   +6 more
doaj   +1 more source

Focal Spot, Spring/Summer 1980 [PDF]

open access: yes, 1980
https://digitalcommons.wustl.edu/focal_spot_archives/1026/thumbnail ...

core   +1 more source

The role of gated myocardial perfusion scintigraphy (GMPS) in myocarditis: A case report and review of the literature [PDF]

open access: yes, 2011
Acute myocarditis is one of the most challenging diagnoses and treatments in cardiology. The acute viral myocarditis diagnosis is usually based on high suspicion, history taking, and physical examination.
Amini, A.   +8 more
core   +2 more sources

Early Autonomic Burden in Prodromal Parkinson's Disease Predicts Cognitive Impairment

open access: yesMovement Disorders, EarlyView.
Abstract Background Autonomic dysfunction is a known contributor to cognitive impairment in Parkinson's disease (PD), but its impact during prodromal stage is unknown. Objective The aim was to determine whether early autonomic burden predicts incident cognitive impairment in prodromal PD.
A. Enrique Martinez‐Nunez   +5 more
wiley   +1 more source

Radiopharmaceutical small-scale preparation in Europe: will we be able to harmonize the situation?

open access: yesEJNMMI Radiopharmacy and Chemistry
Background Radiopharmaceuticals have been considered a special group of medicines in Europe since 1989. The use of radiopharmaceuticals that have marketing authorization should always be the first option in clinical use, however due to their special ...
Estrella Moya   +3 more
doaj   +1 more source

Markierungsverfahren zur Synthese 4-[18F]Fluorprolyl-haltiger Peptide [PDF]

open access: yes, 2002
The requirement of selective radiopharmaceuticals for PET-diagnostics necessitates the development of new labelling methods taking into account the substantial and structural diversity of the compounds to be labelled . Therefore different concepts for $^{
Jelinski, Marianne
core  

Increased Serum Neurofilament Light Chain Levels in Parkinson's Disease Patients Carrying the p.A53T SNCA Mutation: Data from the Parkinson's Progression Markers Initiative Study

open access: yesMovement Disorders, EarlyView.
Abstract Background Serum neurofilament light chain (NfL) levels, a marker of axonal damage, are generally elevated in neurodegenerative conditions, but results in idiopathic Parkinson's disease (iPD) have been inconsistent. The p.A53T SNCA mutation usually leads to a severe form of PD.
Nikolaos Papagiannakis   +213 more
wiley   +1 more source

Expanding a peptide-covalent probe hybrid for PET imaging of S. aureus driven focal infections

open access: yesEJNMMI Radiopharmacy and Chemistry
Background The urgent demand for innovative theranostic strategies to combat bacterial resistance to antibiotics is evident, with substantial implications for global health. Rapid diagnosis of life-threatening infections can expedite treatment, improving
Jyotsna Bhatt Mitra   +7 more
doaj   +1 more source

Discovery and evaluation of a novel 18F-labeled vasopressin 1a receptor PET ligand with peripheral binding specificity

open access: yesActa Pharmaceutica Sinica B
The arginine-vasopressin (AVP) hormone plays a pivotal role in regulating various physiological processes, such as hormone secretion, cardiovascular modulation, and social behavior.
Junqi Hu   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy